ReviewFrontiers in cellular and infection microbiology2026
Integrative neuromodulation in diabetic foot infections: electroacupuncture-driven macrophage reprogramming and synergy with antimicrobial biomaterials.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot infections (DFIs) are characterized by persistent bacterial biofilms and impaired host immune defenses. Within the diabetic microenvironment, peripheral neuropathy disrupts neuro-immune feedback loops, contributing to the arrest of resident macrophages in a pro-inflammatory M1 phenotype. This phenotypic arrest impairs efferocytosis and sustains chronic inflammation, which conventional antimicrobial therapies frequently fail to resolve. Electroacupuncture (EA) serves as a neuromodulatory intervention capable of reversing this immune dysfunction. By stimulating specific somato-autonomic reflexes-including the vagal-adrenal and sympathoadrenal axes-EA activates the systemic cholinergic anti-inflammatory pathway (CAP). The subsequent release of neurotransmitters, acting on receptors such as the α7 nicotinic acetylcholine receptor (α7nAChR) on macrophages, inhibits pro-inflammatory cascades and promotes polarization toward the pro-repair M2 phenotype. Concurrently, EA-induced localized neuropeptide release and vasodilation mitigate the ischemic microenvironment, providing metabolic support for sustained pathogen clearance. Furthermore, this review proposes a translational "Vanguard and Commander" approach, integrating the localized biofilm-disrupting properties of advanced antimicrobial biomaterials (the "vanguard") with the sustained immune reprogramming mediated by EA (the "commander"). This integration links material science with bioelectronic neuromodulation to coordinate the tissue repair process spatiotemporally. Ultimately, this combined approach provides an opioid-sparing, integrative therapeutic strategy for the management of refractory diabetic wound infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.